Fluorescent Light Energy (FLE) as an Adjunctive Therapy in Canine Cutaneous Epitheliotropic Lymphoma (CTCL).

FLE appears safe for canine CTCL but lacks statistically significant efficacy as adjunctive therapy.

This study evaluated fluorescent light energy (FLE; Phovia, Vetoquinol) as an adjunctive photobiomodulation therapy for canine cutaneous epitheliotropic lymphoma (CTCL), a neoplastic skin disease with limited treatment options. Eight client-owned dogs with biopsy-confirmed CTCL received weekly FLE treatments for 6 weeks on one lesion, with an untreated lesion serving as vehicle control, followed by 3-month follow-up. Focal nodular lesions were assessed using RECIST criteria, while diffuse lesions were evaluated using CELESI scoring. Owner-perceived efficacy and quality of life were assessed via OGATE and QoL surveys. Results showed no statistically significant differences between treated and control sites; however, within-subject analyses suggested more favorable lesion progression at FLE-treated sites, with 75% of RECIST-evaluated lesions maintaining stable disease and diffuse lesions demonstrating clinical severity reductions up to 35.3%. Over 66% of owners reported treatment response as 'fair' to 'excellent.' One dog withdrew at Week 3 due to unrelated complications. The authors conclude FLE appears safe as adjunctive CTCL therapy, though statistically significant treatment effects were not demonstrated.

This summary was distilled by AI and may occasionally misinterpret data. Confirm critical details with the primary literature before clinical application.